Fig 1: A SARS-CoV-2 mRNA vaccine incorporated with IL-7 elicits potent immune responses. A Schematic diagram of nucleoside-modified mRNA, encoding the full-length S protein. S spike protein of SARS-CoV-2, SP signal peptide. B HEK-293T cells were transfected with LNP-encapsulated S mRNA (2 µg), IL-7 mRNA (1 µg) or S&IL-7 mRNA (2 μg S mRNA + 1 μg IL-7 mRNA). After 24 h, Western blotting was performed to measure the expression levels of S and IL-7 in the cell lysates (n = 3). C Experimental design. Mice were vaccinated with 20 µg of S mRNA encapsulated in LNP or 10 µg of IL-7 mRNA co-encapsulated with 20 µg of S mRNA in LNP. After 4 weeks of primary immunization, a booster immunization was administered using the same dose as the primary immunization, and serum samples were collected. D–G SARS-CoV-2 S protein-binding IgG titers were detected using ELISA (n = 8). H, I SARS-CoV-2 S protein-binding IgG2a (H) and IgG1 (I) titers in mice following booster immunization (n = 8). J SARS-CoV-2 neutralizing antibodies against the original Wuhan strain in mice following booster immunization were detected using pseudovirus neutralization assay (n = 8)
Fig 2: A RABV mRNA vaccine expressing IL-7 induces durable antibody production and provides long-term protection. A, D Experimental design. 3 weeks (A) or 24 weeks (D) after immunization of mice with G mRNA, G&IL-7 mRNA, or PBS, an intracerebral injection of 50 LD50 of the virulent RABV strain CVS-24 was administered. B, E Changes in body weight are presented with error bars indicating the means ± standard deviation (SD). C, F Survival rates. Intergroup differences in survival rates were assessed using a log-rank test
Fig 3: IL-7 promotes the proliferation of Tfh cells, GC B cells and PCs in mice. C57BL/6 mice were immunized with G mRNA, G&IL-7 mRNA, or PBS, respectively. A Representative flow cytometric plots of Tfh cells in inguinal lymph nodes (LNs) cells. At 7 and 14 dpi, LNs cells were stained with markers specific to Tfh cells (CD4+CXCR5+PD-1+). B Statistical analyses were conducted on CD4+CXCR5+PD-1+ Tfh cell plots (n = 5). C Representative flow cytometric plots of GC B cells in inguinal lymph nodes cells. At 7 and 14 dpi, LNs cells were stained with markers specific to GC B cells (B220+GL7+CD95+). D Statistical analyses were conducted on B220+GL7+CD95+ GC B cell plots (n = 5). E Representative flow cytometric plots of PCs in bone marrow (BM) cells. At 7 and 14 dpi, BM cells were stained with markers specific to PCs (B220lowCD138+). F Statistical analyses were conducted on B220lowCD138+ PCs plots (n = 5)
Fig 4: IL-7 enhances mRNA vaccine-induced antibody production in mice. A Schematic diagram of IL-7 mRNA (0.5 μg, 2.5 μg, and 5 μg) as an adjuvant co-encapsulated with 2.5 μg of G mRNA in LNPs. B Mice were administered G mRNA encapsulated with varying concentrations of IL-7 mRNA. RABV virus-neutralizing antibody (VNA) titers were assessed using fluorescent antibody virus neutralization assays (n = 10). C Mice were immunized via intramuscular injection with G mRNA, G&IL-7 mRNA, or the ITV vaccine. Serum samples were collected starting from week 1 post immunization and continued until week 24. D–H VNA titers were assessed via FAVN assays. IgG, IgG1, IgG2a, and IgG2b levels in the serum were measured by ELISA (n = 10)
Fig 5: The design and characterization of a RABV mRNA vaccine expressing IL-7. A A schematic diagram of nucleoside-modified mRNA encoding G and IL-7. SP: signal peptide. B A schematic diagram illustrating the co-encapsulation of IL-7 mRNA as an adjuvant with G mRNA in LNPs for vaccination. C A representative transmission electron microscopy (TEM) image of LNPs in solution after mRNA encapsulation. Scale bar, 100 nm. D Particle size of LNPs measured using dynamic light scattering (DLS). E HEK-293T cells were transfected with LNP-encapsulated G mRNA (1 μg), IL-7 mRNA (1 μg) or G&IL-7 mRNA (1 μg G mRNA + 1 μg IL-7 mRNA). After 24 h, Western blotting was performed to measure the expression levels of G and IL-7 in the cell lysates (n = 3)
Supplier Page from Abcam for Biotin Anti-IL-7 antibody